India, Nov. 20 -- This week's biotech roundup features significant regulatory milestones, corporate restructuring and strategic dealmaking, alongside clinical developments across oncology, neurology, and rare diseases. Sanofi and Regeneron secured FDA approvals for therapies targeting neurological complications of rare and autoimmune diseases, while Revolution Medicines gained EU authorization for its pancreatic cancer drug. Summit Therapeutics, however, faced an FDA setback for ivonescimab. Meanwhile, Milestone Pharmaceuticals announced workforce and cost-reduction measures, major pharmaceutical companies pursued acquisitions and collaborations, and clinical trial updates highlighted promising survival benefits, Alzheimer's disease data an...